MaaT Pharma: first patient treated in the USA

(CercleFinance.com) - MaaT Pharma announced last night that the first patient to receive its investigational treatment for acute graft-versus-host disease in the United States had done so under a compassionate access program.


This patient, who had already received several lines of treatment, was treated with MaaT013 at City of Hope Hospital near Los Angeles, one of the most prestigious cancer institutions in the United States.

This treatment was carried out under the Food and Drug Administration (FDA)-approved single-patient expanded access program, which allows access to investigational drugs outside clinical trials, when available therapeutic options are limited or non-existent.

In the U.S., this program can be initiated by a treating physician via an Investigational New Drug (IND) application for a single patient.

Dr. Monzr M. Al Malki of City of Hope Hospital says he believes in the technology developed by MaaT, which aims to improve the survival of cancer patients by modulating the immune system.

Copyright (c) 2024 CercleFinance.com. All rights reserved.